InProTher is developing first-in-class immunotherapies against cancer and has pre-clinical proof of concept for broad and curative cancer therapy. Treated animals eliminate their tumors and become resistant to challenge from administered cancer cells. A combination with immune checkpoint inhibitors makes the effect complete in animal models. InProTher's research is based upon research by Associate Professor Peter Johannes Holst and colleagues and international collaborators.